Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Cognitive Function During Pregnancy In Multiple Sclerosis: Is There A Decline In Processing Speed?
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
3-004

PS is a very sensitive measure of global cognitive performance. It is one of the most used neuropsychological measures in people with multiple sclerosis (pwMS), as PS impairment is the earliest and most prevalent cognitive disfunction in pwMS. It is also regarded as a sensitive biomarker for cognitive integrity. 

During pregnancy, literature reports an impairment in PS in late pregnancy and puerperium.

To explore processing speed (PS) during pregnancy in people with multiple sclerosis (pwMS) and healthy women (HCW).

 

We consecutively included 30 pregnant pwMS and 37 HCW between 2018 and 2022. Measurements were collected using the written version of the Symbol Digits Modalities Test (SDMT) at first, second and third trimesters of pregnancy. Statistical analysis was performed with Friedman Test after normality testing. The study received local IEC approval.

PwMS and HCW were similar in age (PwMS mean(SD) 34,57(5,1) vs HCW 33,35(3,9)) and educational level (PwMS 14,9(3,5) vs HCW 16,2(2,1)). 

 

SDMT mean score for the first trimester in pwMS was 57 (SD 8.7); second trimester 54 (SD 8,5) and third trimester 54 (SD 10,4). All scores were within their normative population range. In HCW, first trimester mean score was 60,27 (SD 9,4); second trimester 60 (SD 7.3) and third trimester 59 (SD 6.7).  No statistically differences were found in any of the three trimesters SDMT´s scoring either for PwMS or HCW.

 

Our results showed a stable PS performance during the three trimesters of pregnancy in MS, similary to healthy control pregnant. Unlike previous literature, our data does not support a decreased performance in PS tasks in late pregnancy in MS patients

We could not confirm cognitive vulnerability attributed to MS patients in our sample, as their performance, at least on PS, stays withing normal ranges of their normative population and behaved similar to controls
Authors/Disclosures
Juan Pablo Cuello (Hospital General Universitario Gregorio Maran)
PRESENTER
Juan Pablo Cuello has nothing to disclose.
Ariana Meldaña Rivera Ariana Meldaña Rivera has nothing to disclose.
Yolanda Higueras Yolanda Higueras has nothing to disclose.
Elisa Rodriguez-Toscano, PhD (Universidad Complutense de Madrid) Dr. Rodriguez-Toscano has nothing to disclose.
Jose Manuel Garcia Dominguez (Hospital General Universitario Gregorio Marañón) Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for merck. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Jose Manuel Garcia Dominguez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall.
Haydee Goicochea Briceño haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving as a Consultant for Merck. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving as a Consultant for Almirrall. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Teva. haydee goicochea briceño has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merk. haydee goicochea briceño has received research support from IOMSN.
Elda María Maria Alba Suarez, PhD (Suárez) Mrs. Alba Suarez has nothing to disclose.
Juan De-León Luis juan de-leon ruiz has nothing to disclose.
Carmen Martinez Asensio, MD Mrs. Martinez Asensio has nothing to disclose.
Maria Luisa Martinez Gines, MD Dr. Martinez Gines has nothing to disclose.